UCB Sa operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares UCB Sa with three other
pharmaceutical manufacturers in Europe:
Biomerieux SA
of FRANCE
(2020
sales of 3.12 billion Euros [US$3.79 billion]
),
Ipsen SA
of FRANCE
(2.69 billion Euros [US$3.27 billion]
), and
Lonza Group AG
which is
based in SWITZERLAND
(4.51 billion Swiss Francs [US$4.97 billion]
).
Sales Analysis.
UCB Sa reported sales of 5.35 billion Euro (US$6.50 billion)
for the
year ending
December of 2020.
This
represents
an
increase of 8.8%
versus 2019, when the company's sales were 4.91 billion Euro.
Sales at UCB Sa have increased during each of the previous five years
(and since 2015, sales have increased a total of 38%).